Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD and the HeartRisk population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains a top concern for employers due to its significant impact on healthcare spending and employee productivity. By leveraging artificial intelligence, Cardio Diagnostics aims to provide more precise and personalized risk assessments, enabling early intervention and potentially reducing the burden of heart disease on both individuals and organizations. The company's proprietary Integrated Genetic-Epigenetic Engine powers these tests, offering insights that go beyond traditional risk factors.
The conferences provide a platform for Cardio Diagnostics to directly connect with key stakeholders in the benefits ecosystem. Employers and plan administrators are increasingly seeking innovative solutions to control rising healthcare costs, and the company's AI-driven tools could offer a data-driven approach to population health management. The HeartRisk platform, in particular, is designed to aggregate risk data across a workforce, helping employers identify high-risk groups and tailor wellness programs accordingly.
For the full press release, visit https://ibn.fm/qFRHu. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
Forward-looking statements in this article involve risks and uncertainties. These statements are based on information available as of the date hereof and are subject to various factors, including those detailed in the company's filings with the SEC. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update them unless required by law.
